Loading
Brain Cancer / AGuIX gadolinium-based nanoparticles / Brain Metastases · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 2 registration for a randomized controlled trial evaluating whether AGuIX gadolinium-based nanoparticles, used as a radiosensitizer during stereotactic radiation, reduce local recurrence in brain metastases compared to radiation alone or placebo. No results are currently posted in this registry record; the trial is still recruiting and remains in the planning or early execution phase.
Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole…; age from 18 Years. Intervention: Stereotactic Radiation plus AGuIX gadolinium-based nanopart…; Stereotactic Radiation plus placebo. Compared with: Stereotactic radiation with placebo. n = 134. 2 sites: United States.
This is an active Phase 2 registration for a randomized controlled trial evaluating whether AGuIX gadolinium-based nanoparticles, used as a radiosensitizer during stereotactic radiation, reduce local recurrence in brain metastases compared to radiation alone or placebo. No results are currently posted in this registry record; the trial is still recruiting and remains in the planning or early execution phase.
This is a registry record with no results posted; efficacy and safety data are not yet available.
The source did not state who this applies to in practice.
This is an active Phase 2 interventional trial with no results posted; the registry record describes planned enrollment and primary outcome measures only, representing early-stage evaluation of a novel radiosensitizer in brain metastases.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04899908). This is a study registration, not published results. Lead sponsor: Brigham and Women's Hospital. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 134 participants (ESTIMATED). Conditions: Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor. Interventions: RADIATION: Stereotactic Radiation; DRUG: AGuIX gadolinium-based nanoparticles; OTHER: Placebo. Primary outcome measures: Local Recurrence , From enrollment to 6 months. Brief summary: The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.